Technoculture develops electrochemical sensing technology to enable faster, more affordable blood tests, aiming to improve diagnostic accessibility and patient outcomes. By leveraging advanced electrochemical methods, the platform can detect biomarkers directly from blood samples, reducing the need for complex laboratory equipment and streamlining clinical workflows.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional blood tests rely on multi-step laboratory assays that are time‑consuming, require bulky equipment, and often delay critical diagnostic information. This slows clinical decision‑making and can negatively impact patient outcomes, especially in urgent care settings.
Solution
Technoculture develops electrochemical sensing platforms that convert biochemical reactions in blood samples into rapid electronic readouts. By integrating these compact sensors into existing laboratory and point‑of‑care workflows, the company enables clinicians to obtain quantitative test results within minutes instead of hours. The technology leverages high‑sensitivity electrode arrays and proprietary surface chemistries to detect a broad range of biomarkers with accuracy comparable to conventional assays. Results are transmitted digitally to laboratory information systems, facilitating seamless data capture and immediate clinical interpretation.
Target Audience
Primary customers are clinical laboratories, hospital pathology departments, and point‑of‑care providers such as urgent care clinics and emergency departments seeking faster blood diagnostics.
Features
- Miniaturized electrochemical sensor cartridges that replace bulk reagent‑based assay kits
- High‑throughput multiplex detection of multiple blood biomarkers on a single platform
- Real‑time electronic readout with sub‑minute turnaround time
- Compatibility with standard laboratory information management systems via API integration
- Low power consumption and disposable sensor design for point‑of‑care deployment